CombiChem Outside Collaborations May End After Purchase By DuPont
The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.
You may also be interested in...
Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials